Ho­mol­o­gy lays off staff, paus­es rare meta­bol­ic dis­ease tri­al de­spite clin­i­cal hold lift

De­spite get­ting the all-clear from the FDA to restart a clin­i­cal tri­al, a biotech is in­stead paus­ing en­roll­ment and dos­ing to re­fo­cus on an­oth­er can­di­date and add to its bank.

Ho­mol­o­gy Med­i­cines put out its Q2 earn­ings re­port ear­ly Tues­day, not­ing that its run­way will now last through Q4 2024. But it doesn’t come with­out a cost, in­clud­ing trim­ming the staff and a “pri­or­i­ti­za­tion” of its PKU clin­i­cal ef­forts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER